Evaluation of clopidogrel impact on canine platelet function using flow cytometry and thromboelastography platelet...

Area of Science:

• Veterinary Medicine
• Pharmacology
• Hematology

Background:

• Clopidogrel is used in veterinary medicine to reduce platelet function, but optimal dosages are debated.
• This study evaluated the antiplatelet effects of a recommended dosage of clopidogrel in dogs.

Purpose of the Study:

• To assess the antiplatelet efficacy and safety of a specific clopidogrel dosage in canine patients.
• To validate thromboelastography (TEG) and flow cytometry as monitoring tools for antiplatelet therapy in dogs.

Main Methods:

• Five dogs received either clopidogrel (1 mg/kg PO q24h) or placebo, with a 14-day washout period.
• Platelet function was assessed using TEG and flow cytometry at baseline and day 7.
• Clinicopathological evaluation included complete blood count and biochemical analyses.

Main Results:

• Clopidogrel significantly reduced adenosine diphosphate (ADP)-induced clot strength, indicating effective platelet inhibition.
• Flow cytometry showed marked inhibition of platelet activation under ADP and epinephrine stimulation.
• Hematological and biochemical parameters remained stable, demonstrating the safety of clopidogrel.

Conclusions:

• Low-dose (1 mg/kg) clopidogrel is effective and safe for canine antiplatelet therapy without a loading dose.
• TEG and flow cytometry are effective for assessing clopidogrel responsiveness in dogs, aiding therapy optimization.